| Literature DB >> 24980189 |
Laura S Mertens1, Yann Neuzillet2, Simon Horenblas1, Bas W G van Rhijn1.
Abstract
Bladder cancer is divided into two entities: non-muscle-invasive (NMIBC) and muscle invasive bladder cancer. NMIBC represents 75% of primary diagnoses and is characterized by frequent recurrence but a low risk of mortality. Throughout urological history, significant progress in detection, diagnosis, and treatment of NMIBC has been made. However, bladder cancer remains a heterogeneous disease with varying pathology, molecular background, diagnostic options, and subsequent therapies for the individual patient. Although significant progress has been made over the years, the improvement of bladder cancer outcomes remains the goal of future research.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24980189 DOI: 10.1038/nrurol.2014.130
Source DB: PubMed Journal: Nat Rev Urol ISSN: 1759-4812 Impact factor: 14.432